Respilon Production S.R.O. - 719705 - 04/20/2026

Why It Matters

The letter threatens market access for Respilon’s OTC drugs in the United States, potentially disrupting supply chains and revenue, while underscoring the FDA’s strict enforcement of CGMP standards for foreign manufacturers.

Key Takeaways

• FDA issued warning letter for CGMP violations at Respilon Production
• No identity testing of incoming components flagged as critical failure
• Stability studies missing despite expiration dates on product labels
• Process validation and method verification not documented per 21 CFR 211
• FDA may block US entry of products until compliance achieved

Pulse Analysis

The FDA’s oversight of foreign drug manufacturers has intensified as the agency seeks to protect U.S. consumers from substandard products. Under the Federal Food, Drug, and Cosmetic Act, any facility that markets over‑the‑counter medicines in the United States must adhere to the same CGMP requirements as domestic plants. Recent inspections have revealed that gaps in testing, documentation, and validation are common pain points for overseas producers, prompting the FDA to issue formal warning letters that can halt imports and damage brand reputation.

Respilon Production S.R.O. received a detailed citation highlighting five core deficiencies. The firm failed to conduct identity testing on each incoming component, omitted stability studies despite labeling expiration dates, and lacked validated production and analytical procedures. Incomplete laboratory records further compounded the risk, leaving the agency to deem the products adulterated. Such violations not only jeopardize patient safety but also expose the company to import refusals, product detentions, and potential loss of market share in the lucrative U.S. OTC segment.

To regain compliance, Respilon must engage a qualified CGMP consultant, conduct a comprehensive six‑system audit, and implement corrective and preventive actions within the FDA‑mandated 15‑day window. The firm’s response will be scrutinized before any future shipments are allowed entry. This case serves as a cautionary tale for all foreign drug manufacturers: robust quality systems, thorough documentation, and proactive engagement with regulators are essential to maintain uninterrupted access to the U.S. market.